Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in:

11-04-2024 | NSCLC | Original Article

No prognostic impact of staging bone scan in patients with stage IA non-small cell lung cancer

Authors: Xia Zheng, Chunxia Li, Jing Ai, Guili Dong, Man Long, Mingyi Li, Shilin Qiu, Yanni Huang, Guangjun Yang, Tao Zhang, Zhenhui Li

Published in: Annals of Nuclear Medicine | Issue 7/2024

Login to get access

Abstract

Objective

To investigate the survival benefit of preoperative bone scan in asymptomatic patients with early-stage non-small cell lung cancer (NSCLC).

Methods

This retrospective study included patients with radical resection for stage T1N0M0 NSCLC between March 2013 and December 2018. During postoperative follow-up, we monitored patient survival and the development of bone metastasis. We compared overall survival, bone metastasis-free survival, and recurrence-free survival in patients with or without preoperative bone scan. Propensity score matching and inverse probability of treatment weighting were used to minimize election bias.

Results

A total of 868 patients (58.19 ± 9.69 years; 415 men) were included in the study. Of 87.7% (761 of 868) underwent preoperative bone scan. In the multivariable analyses, bone scan did not improve overall survival (hazard ratio [HR] 1.49; 95% confidence intervals [CI] 0.91–2.42; p = 0.113), bone metastasis-free survival (HR 1.18; 95% CI 0.73–1.90; p = 0.551), and recurrence-free survival (HR 0.89; 95% CI 0.58–1.39; p = 0.618). Similar results were obtained after propensity score matching (overall survival [HR 1.28; 95% CI 0.74–2.23; p = 0.379], bone metastasis-free survival [HR 1.00; 95% CI 0.58–1.72; p = 0.997], and recurrence-free survival [HR 0.76; 95% CI 0.46–1.24; p = 0.270]) and inverse probability of treatment weighting.

Conclusion

There were no significant differences in overall survival, bone metastasis-free survival, and recurrence-free survival between asymptomatic patients with clinical stage IA NSCLC with or without preoperative bone scan.
Appendix
Available only for authorised users
Literature
1.
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–237.CrossRefPubMed
2.
Weissensteiner J, Babusikova E. The value of human epididymis protein 4 (HE4) as a serum tumor marker for accurate bone metastases finding by whole-body bone scintigraphy in lung cancer patients. Neoplasma. 2019;66(6):1024–30.CrossRefPubMed
3.
Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol. 2013;31(4):262–9.CrossRefPubMed
4.
Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer (Amsterdam, Netherlands). 2014;86(1):78–84.CrossRefPubMed
5.
da Silva GT, Bergmann A, Thuler LCS. Incidence and risk factors for bone metastasis in non-small cell lung cancer. Asian Pac J Cancer Prev APJCP. 2019;20(1):45–51.CrossRefPubMed
6.
Jiao W, Qiu T. Necessity of preoperative bone scintigraphy for cT1N0 lung cancer: evidence from retrospective to prospective study. Thoracic Cancer. 2021;12(4):413–4.CrossRefPubMedPubMedCentral
7.
Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley-Price P. The incidence and clinical impact of bone metastases in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2015;89(2):197–202.CrossRefPubMed
8.
Wu S, Pan Y, Mao Y, Chen Y, He Y. Current progress and mechanisms of bone metastasis in lung cancer: a narrative review. Transl Lung Cancer Res. 2021;10(1):439–51.CrossRefPubMedPubMedCentral
9.
Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637–42.CrossRefPubMed
10.
Chen WM, Chen M, Hsu JG, Lee TS, Shia BC, Wu SY. Use of preoperative FDG PET/CT and survival of patients with resectable non-small cell lung cancer. Radiology. 2022;305(1):219–27.CrossRefPubMed
11.
Israel O, Pellet O, Biassoni L, De Palma D, Estrada-Lobato E, Gnanasegaran G, et al. Two decades of SPECT/CT—the coming of age of a technology: an updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46(10):1990–2012.CrossRefPubMedPubMedCentral
12.
Li H, Hu H, Wang R, Zhang Y, Xiang J, Liu Q, et al. When should 99mTc bone scintigraphy be performed in cT1N0 non-small cell lung cancer patients? Medicine. 2015;94(51): e2309.CrossRefPubMedPubMedCentral
13.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(1):39–51.
14.
Kandathil A, Kay FU, Butt YM, Wachsmann JW, Subramaniam RM. Role of FDG PET/CT in the eighth edition of TNM staging of non-small cell lung cancer. Radiogr Rev Publ Radiol Soc N Am. 2018;38(7):2134–49.
15.
Kim H, Goo JM, Suh YJ, Hwang EJ, Park CM, Kim YT. Measurement of multiple solid portions in part-solid nodules for T categorization: evaluation of prognostic implication. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13(12):1864–72.
16.
Kim H, Goo JM, Kim YT, Park CM. Clinical T category of non-small cell lung cancers: prognostic performance of unidimensional versus bidimensional measurements at CT. Radiology. 2019;290(3):807–13.CrossRefPubMed
17.
Kim H, Goo JM, Kim YT, Park CM. Clinical T categorization in stage IA lung adenocarcinomas: prognostic implications of CT display window settings for solid portion measurement. Eur Radiol. 2019;29(11):6069–79.CrossRefPubMed
18.
Subramanian M, McMurry T, Meyers BF, Puri V, Kozower BD. Long-term results for clinical stage IA lung cancer: comparing lobectomy and sublobar resection. Ann Thorac Surg. 2018;106(2):375–81.CrossRefPubMedPubMedCentral
19.
Gregoire J. Guiding principles in the management of synchronous and metachronous primary non-small cell lung cancer. Thorac Cardiovasc Surg. 2021;31(3):237–54.
20.
Wang Y, Yeung JC, Hanna WC, Allison F, Paul NS, Waddell TK, et al. Metachronous or synchronous primary lung cancer in the era of computed tomography surveillance. J Thorac Cardiovasc Surg. 2019;157(3):1196–202.CrossRefPubMed
21.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMed
22.
Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(27):3097–104.CrossRef
23.
Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49(8):907–16.CrossRefPubMed
24.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(9):1243–60.
25.
Wang H, Zhang Y, Zhu H, Yu J. Risk factors for bone metastasis in completely resected non-small-cell lung cancer. Future Oncol (London, England). 2017;13(8):695–704.CrossRef
26.
Wu XT, Zhou JW, Pan LC, Ge T. Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer. J Int Med Res. 2020;48(5):300060520925644.CrossRefPubMed
27.
28.
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, et al. Bone metastases. Nat Rev Dis Primers. 2020;6(1):83.CrossRefPubMed
29.
Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2011;6(3):576–82.
30.
Gomez DR, Liao KP, Swisher SG, Blumenschein GR, Erasmus JJ, Buchholz TA, et al. Time to treatment as a quality metric in lung cancer: staging studies, time to treatment, and patient survival. Radiother Oncol. 2015;115(2):257–63.CrossRefPubMed
31.
Richardet E, Villavicencio R, Hernandez P, Acosta L, Molina M, Dicalbo L, et al. P1.09: delays in the diagnosis and treatment of lung cancer. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(10):S185.
32.
33.
Port JL, Kent MS, Korst RJ, Libby D, Pasmantier M, Altorki NK. Tumor size predicts survival within stage IA non-small cell lung cancer. Chest. 2003;124(5):1828–33.CrossRefPubMed
34.
Roviaro G, Varoli F, Vergani C, Nucca O, Maciocco M, Grignani F. Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. Chest. 2004;126(3):725–32.CrossRefPubMed
35.
Nam JG, Hong H, Choi SH, Park CM, Goo JM, Kim YT, et al. No prognostic impact of staging brain MRI in patients with stage IA non-small cell lung cancer. Radiology. 2022;303(3):632–43.CrossRefPubMed
36.
Metadata
Title
No prognostic impact of staging bone scan in patients with stage IA non-small cell lung cancer
Authors
Xia Zheng
Chunxia Li
Jing Ai
Guili Dong
Man Long
Mingyi Li
Shilin Qiu
Yanni Huang
Guangjun Yang
Tao Zhang
Zhenhui Li
Publication date
11-04-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 7/2024
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01927-3

Other articles of this Issue 7/2024

Diagnostic performance of a deep-learning model using 18F-FDG PET/CT for evaluating recurrence after radiation therapy in patients with lung cancer

Fundamental evaluation regarding the relationship between albumin-binding and tumor accumulation of PSMA-targeting radioligands

  • Original Article

Correction to: Annals of Nuclear Medicine

  • Publisher Correction

Animal PET scanner with a large field of view is suitable for high-throughput scanning of rodents

Safety and efficacy of multiple-dose versus single-dose MIBG therapy in patients with refractory pheochromocytoma and paraganglioma: a single-center retrospective analysis

Correction: Novel indices representing heterogeneous distributions of myocardial perfusion imaging

  • Open Access
  • Correction